4.6500 0.00 (0.00%)
After hours: 4:30PM EDT
|Bid||4.5200 x 4000|
|Ask||4.6400 x 1100|
|Day's Range||4.3600 - 4.8150|
|52 Week Range||2.6400 - 19.6500|
|Beta (3Y Monthly)||2.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.60|
Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug Administration related to the inspection of its Somerset, New Jersey manufacturing facility in July and August 2018. Akorn said it is committed to the highest standards of quality and compliance and will continue to work collaboratively with the FDA to resolve issues addressed in the warning letter.
The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.
said Tuesday that it received a warning letter from the U.S. Food & Drug Administration regarding an inspection of the company's Somerset, New Jersey facility in July and August 2018. The Lake Forest, Illinois-based company said in a statement that it will respond to the FDA letter within the required 15 working days. "Akorn is committed to resolving the warning letter in a comprehensive and effective manner," Douglas Boothe, president and CEO, said in the statement.
Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker. The FDA warning is the second that Akorn has received this year and follows an inspection of the company's Somerset, New Jersey-based plant in July and August 2018. In January, the agency issued a warning letter for Akorn's other manufacturing plant in Decatur, Illinois after the drugmaker did not resolve previously highlighted violations such as failure to follow procedures to prevent contamination of drugs produced at the plant.
Generics company Akorn Inc. said Tuesday it has received a warnings letter from the U.S. Food and Drug Administration, relating to the inspection of a facility in New Jersey in July and August of 2018. The company said it is committed to the highest levels of quality and compliance and will work with the regulator to address all issues raised in the letter. "Earlier this year, Akorn launched a company-wide action plan to improve the timing and effectiveness of our operations, quality systems and compliance enhancement initiatives, with an emphasis on transparency and quality," Akorn Chief Executive Douglas Boothe said in a statement. The company remains confident in the quality of products made at the facility, which is located in Somerset. Shares were halted for the news, but have gained 39.5% in 2019, while the S&P 500 has gained 17.5%.
Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter. The Company will respond to the FDA letter within the required 15 working days from receipt of the letter. Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “Akorn is committed to resolving the warning letter in a comprehensive and effective manner.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Akorn Inc NASDAQ/NGS:AKRXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AKRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 23. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AKRX totaled $604 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at http://investors.akorn.com/events-and-presentations. The webcast may include forward-looking statements about, among other things, the Company’s business plans and initiatives, the Company’s commitments to the FDA and remediation efforts, disruptions during the Standstill Period, the Company’s anticipated future operating and financial performance, business plans and prospects, product pipeline, including filings, approvals and launches, capital allocation, debt refinancing, and potential dispositions, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) Kaleido Biosciences Inc (NASDAQ: KLDO ) Down In The ...
LAKE FOREST, Ill., May 20, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.
Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY. A live webcast of the presentation can be accessed on the investor page of Akorn's website at http://investors.akorn.com. A replay of the webcast will also be available for 90 days on Akorn's website following the conference.
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lake Forest, Illinois-based company said it had a loss of 65 cents. Losses, adjusted for one-time gains and costs, came to 10 cents per share. The results exceeded Wall Street ...
-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 -- Akorn,.
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big losses like the plague. So take a moment to sympathize with the long term shareholders of Akorn, Inc. (NA...
Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Illinois, captioned Juan v. Akorn Inc. et al., (Case No. 19-cv-2720), on behalf of persons and entities that purchased or otherwise acquired Akorn, Inc. (NASDAQ: AKRX) (“Akorn” or the “Company”) securities between May 2, 2018 and January 8, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). On January 9, 2019, Akorn announced that it had received a warning letter “dated January 4, from the U.S. Food and Drug Administration (FDA) related to an inspection of its Decatur, Illinois manufacturing facility in April and May of 2018.” The warning letter from the FDA detailed a laundry list of “significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.” On this news, shares of Akorn fell $0.46 per share or over 11.6% to close at $3.48 per share on January 9, 2019, thereby injuring investors.
NEW YORK, April 22, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX) securities between August 1, 2018 and January 8, 2019, inclusive (the “Class Period”). Akorn investors have until April 22, 2019 to file a lead plaintiff motion in this class action. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com.